🔗 Permalink

Inventor profile of:

Stephen Kaminsky

City:

Bronx, New York

Country:

United States

Published Applications:

Last publication date:

2025-10-16

Top Assignees for applications by Stephen Kaminsky

The entities that hold a legal rights for patent applications filed by inventor Kaminsky Stephen:

Theraclone Sciences, Inc. 13 Seattle, WA United States
The Scripps Research Institute 13 La Jolla, CA United States
International AIDS Vaccine Initiative 8 New York, NY United States
International AIDS Vaccine Initiative Inc. 5 New York, NY United States
CORNELL UNIVERSITY 1 Ithaca, NY United States

Recent patent applications by Kaminsky Stephen

Stephen Kaminsky from Bronx, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-10-16

US20250320281A1

Chemistry; metallurgy

METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES

#2 | 2024-10-17

US20240343782A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#3 | 2024-09-19

US20240307517A1

Human necessities

DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION FENTANYL-CONJUGATE VACCINE TO TREAT FENTANYL ADDICTION

#4 | 2024-04-25

US20240132578A1

Chemistry; metallurgy

METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES

#5 | 2023-09-21

US20230295278A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#6 | 2023-01-26

US20230027965A1

Chemistry; metallurgy

Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies

#7 | 2021-02-11

US20210040186A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#8 | 2020-01-23

US20200024330A1

Chemistry; metallurgy

Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies

#9 | 2019-11-07

US20190338017A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#10 | 2019-06-06

US20190169273A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#11 | 2019-01-31

US20190031742A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#12 | 2018-03-01

US20180057570A1

Chemistry; metallurgy

Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody

#13 | 2016-09-15

US20160264649A1

Chemistry; metallurgy

Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody

#14 | 2015-08-06

US20150218257A1

Chemistry; metallurgy

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

#15 | 2014-07-24

US20140205612A1

Chemistry; metallurgy

Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody

InventorID:

846024 ⎘